Weekly Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings as of Apr 20, 2018

April 20, 2018 - By Damon Whitfield

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Corporate Logo

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

A total of 8 analysts rate Adamas Pharmaceuticals (NASDAQ:ADMS) as follows: 8 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ADMS) has 13 ratings reports on Apr 20, 2018 according to StockzIntelligence. In Wednesday, November 8 report Noble Financial maintained it with “Buy” rating and $48.0 target. On Tuesday, February 20 the rating was maintained by Mizuho with “Buy”. On Wednesday, November 29 the firm has “Buy” rating by Northland Capital given. On Friday, March 9 the rating was maintained by Mizuho with “Buy”. On Friday, February 23 the rating was maintained by Needham with “Buy”. On Friday, November 3 the firm has “Buy” rating by Mizuho given. The stock rating was maintained by Piper Jaffray with “Buy” on Tuesday, January 30. On Tuesday, January 23 the firm earned “Buy” rating by Mizuho. On Wednesday, April 4 the stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Leerink Swann. On Thursday, February 22 Piper Jaffray maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating. Piper Jaffray has “Buy” rating and $49.0 target. Listed here are Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) PTs and latest ratings.

04/04/2018 Broker: Leerink Swann Rating: Buy New Target: $31.0000 Initiate
27/03/2018 Broker: Bank of America Rating: Buy New Target: $39 Initiates Coverage On
09/03/2018 Broker: Mizuho Rating: Buy New Target: $49.0 Maintain
22/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $49.0 Maintain
23/02/2018 Broker: Needham Rating: Buy New Target: $40.0 Maintain
20/02/2018 Broker: Evercore Rating: Buy New Target: $85.0 Maintain
20/02/2018 Broker: Mizuho Rating: Buy New Target: $48.0 Maintain
30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $55.0 Maintain
23/01/2018 Broker: Mizuho Rating: Buy New Target: $48.0 Maintain
29/11/2017 Broker: Northland Capital Rating: Buy New Target: $70.0 Initiate

ADMS touched $27.67 during the last trading session after $1.82 change.Adamas Pharmaceuticals, Inc. has 1.77 million shares volume, 65.14% up from normal. ADMS is uptrending and has moved 35.83% since April 20, 2017. ADMS outperformed the S&P500 by 24.28%.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders.The company has $741.76 million market cap. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease.Last it reported negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.